Back To: Home : Featured Technology : Reagents/Proteins

CLICK HERE FOR WHAT'S NEW IN:
 

NCI taps Intrinsic Bioprobes to develop MS immunoassays for detection of cancer-related proteins
May 2009
SHARING OPTIONS:

TEMPE, Ariz.Intrinsic Bioprobes Inc., a privately held biotech focused on developing mass spectrometry-based assays and platforms for rapid and sensitive protein biomarker analysis, announced in April that it entered into a two-and-a-half-year, $1.27 million contract with the National Cancer Institute (NCI) to develop technologies for accurate measurement of cancer-related proteins and peptides that improve diagnostic capabilities by effectively discerning diseased from non-diseased states.
 
The contract is in support of NCI's Clinical Proteomic Technologies for Cancer initiative to assess and apply proteomic technologies and data resources to solve critical problems in cancer research.

Back


PAGE UTILITIES


CONTACT US
DDNEWS
Published by Old River Publications LLC
19035 Old Detroit Road
Rocky River, OH USA 44116
Ph: 440-331-6600  |  Fax: 440-331-7563
 
© Copyright 2020 Old River Publications LLC. All righs reserved.  |  Web site managed and designed by OffWhite.